Sorry for the late reply I only have 3 messages a day I can write.
As far as products RBII and OPTI do differ but work on the same principle basis bottom line.
The comparison everyone is looking at is that both companies have adjusted their main product focus to disinfection/sanitization to aid in the defense of the covid 19 spread.
OPTI'S products are a Far UVC LED technology that use high intensity uv light to disrupt the DNA blocks of viruses essentially killing it after about 10 minutes of contact. Products are the iwand, rover and the new temperature scanner.
RBII shifted their focus from their normal operations to begin mass production of their oxi-thymol disinfectant which is applied by use of a fogging machine to completely and evenly cover surfaces killing contaminates on contact. Product drys quickly and does not leave any residue.
Both companies are expanding at an accelerated rate to meet product demand. OPTI I know has had difficulties keeping up with demand in the past, RBII has built an added bottling plant recently and say they should have no issues with product supply plus some buzz around contracts and product sales in grocery outlets.
As both are covid 19 plays currently all previous activities are essentially not in the investor's focus any longer so as an investor in RBII I'm hoping that the current CEO had learned from his past mistakes and going forward.
The biggest factor is the share structure OPTI is just being used an a base line given its success as of late. RBII has a smaller AS and Float. These companies products may not be exactly the same but the principle and basis are, they are both covid 19 plays right now, they both have products leaned toward sanitization, they share a relatively similar share structure and both are in high demand atm.
Everything is speculative until we see Q1 and Q2 as well as go current but if it's as good as Art Hall says it is I think RBII has as good of shot as any to succeed only time will tell.
